Biocon Inks Licensing and Supply Agreement with Handok to Commercialize Synthetic Liraglutide

Biocon on Friday, signed a licensing and supply agreement with South Korea, Handok, to commercialize its vertically-integrated and complex drug product, Synthetic Liraglutide.

Liraglutide is an injection in a pre-filled pen, used in the treatment of chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity, the company stated.

Biocon will develop, manufacture and supply the drug product and Handok will obtain regulatory approval and commercialize it in the South Korean market. 

Handok is a leading company in South Korea for managing diabetes, from diagnosis to treatment and care.

Open Demat A/C